BioAtla Inc
BCAB
Market Cap$32.6M
Close$
$0.66
39.3% upside
Current Fair Value
39.3% upsideUndervalued by 39.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $32.60 Million |
|---|---|
| Enterprise Value | $-15,613,872.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-1.44 |
| Beta | 1.07 |
| Outstanding Shares | 49,949,546 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -0.4 |
|---|---|
| PEG | 0.59 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -1.23 |
| Enterprise Value to EBIT | 0.18 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.05 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About BioAtla Inc
36 employeesBioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms...